Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission

Addex Reports Full Year 2020 Financial Results and Provides Corporate Update

Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021

Addex to Present at the H.C. Wainwright Global Life Sciences Conference

Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

Addex GABAB Positive Allosteric Modulators Demonstrate Promise in Alcohol Use Disorder

Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Addex to Present at the Baader Helvea Swiss Equities Conference

Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities

Addex Announces Pricing of $10.0 Million Global Offering